The majority of patients with Non-Small Cell Lung Cancer (NSCLC) are diagnosed with advanced disease (Stage IV).  The site of the metastasis as well as the underlying disease influences the outcome and the patient’s quality of life. OBJECTIVES: To evaluate the impact of brain metastases compared with other metastatic sites on health-related quality of life (EQ-5D) and physician-perceived life expectancy in stage IV NSCLC patients METHODS: Data were drawn from the Adelphi NSCLC Disease-Specific Programme (DSP^®), a cross-sectional survey of 120 pulmonologists and oncologists and their NSCLC patients conducted between July and September 2010 in France and Germany. Each physician completed detailed record forms on 10 advanced patients being actively treated for NSCLC.  Patients were invited to complete an equivalent patient self-completion questionnaire (PSC) which included the EQ-5D. Analysis was conducted on patients with only one metastatic site, either brain, contralateral lung, adrenal gland, bone or liver. Mann-Whitney tests were used to assess the differences between metastatic sites RESULTS: